Turnstone Biologics Corp. (TSBX)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.44 |
Market Cap | 10.18M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -2.28 |
PE Ratio (ttm) | -0.19 |
Forward PE | n/a |
Analyst | Hold |
Ask | 0.45 |
Volume | 49,108 |
Avg. Volume (20D) | 196,343 |
Open | 0.44 |
Previous Close | 0.45 |
Day's Range | 0.43 - 0.47 |
52-Week Range | 0.40 - 5.75 |
Beta | undefined |
About TSBX
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical dev...
Analyst Forecast
According to 2 analyst ratings, the average rating for TSBX stock is "Hold." The 12-month stock price forecast is $2.12, which is an increase of 381.82% from the latest price.